Experimental and Translational Theranostic Group
In Dr Kathy Chan’s group, we combine Kinetics, Cellular targeting, Harnessing immunotherapy and Advance imaging technologies to develop Novel theranostics to meet clinical demands.
Heterogenous target expression in cancer cells remains one of the main limitations to the effectiveness of cancer therapies, directly impacting patient outcomes. Our approach allows for the strategic development of ‘match-pair’ radiopharmaceuticals (radiotheranostics), enabling the visualisation and quantification of the presence and engagement of therapeutic target in vivo using an imaging method, prior to switching to the radiolabelled therapeutic version. Radiotheranostics facilitate tumour burden visualisation and assessment of therapy’s impact on target expression, allowing clinicians to ‘treat what you see’ to facilitate personalised treatment strategies.
We are dedicated to developing personalised treatment strategies to enhance tumour response by combining targeted-radionuclide therapy with immunotherapy. Our team collaborates closely with the Centre for Cancer Imaging, which uses cutting-edge imaging techniques to study cancer development and treatment response, as well as the Centre for Cancer Drug Discovery, the largest academic cancer drug discovery and development group globally, covering all aspects of new drug development.
Our research is centered on developing the next-generation 'radiotheranostics' — an integrated approach combining of whole-body radionuclide imaging and therapeutic tools to improve cancer detection and treatment. We also explore the biological effects of radionuclide therapies using advanced preclinical models, aiming to uncover new druggable targets and improve treatment outcomes.
Dr Kathy Chan
Group Leader:
Experimental and Translational Theranostic
Dr Chan is a radiochemist with expertise in leading the development of novel radiopharmaceutical agents for disease imaging and therapy.
Recent discoveries
